EUCTR2020-003370-41-ES进行中（未招募）1 期
Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccines with AS03 Adjuvant in Adults 18 Years of Age and Older as a Primary Series and Immunogenicity and Safety of a Booster Dose of SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (two Monovalent and one Bivalent)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 5,412
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Aged 18 years or older on the day of inclusion.
- •-A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies:
- •Is of non-childbearing potential. To be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year or surgically sterile. OR Is of childbearing potential and agrees to use an effective contraceptive method or abstinence from at least 4 weeks prior to the first vaccination until at least 12 weeks after the second vaccination. A participant of childbearing potential must have a negative highlysensitive pregnancy test (urine or serum as required by local regulation) within 4 hours before any dose of study intervention.
- •-Informed consent form has been signed and dated.
- •-Able to attend all scheduled visits and to comply with all study procedures.
- •-SARS-CoV-2 rapid serodiagnostic test performed at the time of enrollment to detect presence of SARS-CoV-2 antibodies (Original Phase 2 Cohort).
- •-For persons living with human immunodeficiency virus (HIV), stable HIV infection determined by participant currently on antiretrovirals with CD4 count > 200/mm3.
- •-Does not intend to receive an authorized/approved COVID-19 vaccine from first vaccination to 3 weeks after the second vaccination despite encouragement by the investigator to receive the authorized vaccine available to them at the time of enrollment.
- •-Supplemental cohorts: for participants originally enrolled in the Phase II cohort of the study, informed consent has to be signed and dated for transitioning to Supplemental Cohort 2.
- •-Supplemental cohorts, booster arms: received a complete primary vaccination series with an authorized/conditionally approved mRNA COVID-19 vaccine (mRNA-1273 [Moderna] or BNT162b2 [Pfizer/BioNTech]) or adenovirus-vectored COVID-19 vaccine (ChAdOx1nCoV-19 [Oxford University/AstraZeneca] or Ad26.CoV2.S [J&J/Janssen]), with the last dose administered a minimum of 4 months prior to inclusion but not longer than 10 months prior to inclusion.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 5084
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 328
排除标准
- •-Known systemic hypersensitivity to any of the vaccine components, or history of a lifethreatening reaction to a vaccine containing any of the same substances.
- •-Dementia or any other cognitive condition at a stage that could interfere with following the trial procedures based on Investigator or designee’s judgment.
- •-Self-reported thrombocytopenia, contraindicating intramuscular (IM) vaccination based on
- •Investigator’s judgment.
- •-Bleeding disorder, or receipt of anticoagulants in the past 21 days preceding inclusion, contraindicating IM vaccination based on Investigator’s judgment.
- •-Unstable acute or chronic illness that in the opinion of the Investigator or designee poses additional risk as a result of participation or that could interfere with the study procedures.
- •-Receipt of solid-organ or bone marrow transplants in the past 180 days.
- •-Receipt of anti-cancer chemotherapy in the last 90 days.
- •-Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature = 38.0°C [= 100.4°F]). A prospective participant should not be included in the trial until the condition has resolved or the febrile event has subsided.
- •-Receipt of any vaccine in the 30 days preceding or on the day of the first study vaccination or planned receipt of any vaccine between the first study vaccination and in the 30 days following the second study vaccination except for influenza vaccination, which may be received at any time in relation to study intervention.
- •-Applicable to Original Phase II Cohort, Supplemental Cohort 1 and Cohort 2 Comparator Group, and Supplemental Variant Prime Cohort 3 Groups: Prior administration of a coronavirus vaccine (SARS-CoV-2, SARS-CoV, Middle East Respiratory Syndrome
- •[MERS-CoV]).
- •-Participation at the time of trial enrollment (or in the 30 days preceding the first trial vaccination) or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure.
- •-Exclusion criterion for the Supplemental Cohort 1 and Cohort 2 comparator group and for
- •the 3 Supplemental Variant Prime Cohort 3 groups: positive rapid diagnostic test for SARS-CoV-2 antibodies at time of enrollment.
- •-Exclusion criterion for participants in Supplemental Cohort 2 who were primed as participant in the Original Phase II Cohort of the present study): Receipt of authorized/conditionally approved COVID-19 vaccine after enrollment in Original Phase 2Cohort.
- •-Exclusion criterion for all Booster groups: Documented virologically-confirmed SARS-CoV2 infection (by NAAT) after first dose of primary immunization.
研究者
相似试验
Unknown
3 期
Study of Recombinant Protein Vaccine with Adjuvant against COVID-19 in Adults 18 Years of Age and Older.COVID-19PACTR20201152310190334,520
已完成
不适用
Immunogenicity and safety of SARS-CoV-2 (COVID-19 virus) vaccine in liver transplant recipientsImmunogenicity and safety of SARS-CoV-2 vaccine in liver transplant recipientsliver transplant, vaccine, COVID-19, SARS-CoV-2, safetyTCTR20210526004Faculty of medicine, Chulalongkorn university60
尚未招募
不适用
Immunogenicity and safety of SARS-CoV-2 (COVID-19 virus) vaccine in patients with hepatocellular carcinomaImmunogenicity and safety of SARS-CoV-2 vaccine in patients with hepatocellular carcinomaCOVID-19, vaccine, hepatocellular carcinoma, SARS-CoV-2TCTR20210525005Faculty of Medicine, Chulalongkorn university60
Unknown
1 期
Safety and Immunogenicity of the Malaria Vaccine Candidate BK-SE36 in Healthy Malaria-Exposed African Children Living in Burkina FasoMalariaPACTR201411000934120obelpharma Co., Ltd108
招募中
1 期
Safety and Immunogenicity of Razi Cov-2 recombinant Spike protein vaccine (RAZI Cov Pars) in healthy children and adolescents aged 5-17 yearsIRCT20201214049709N5Razi Vaccine and Serum Research Institute420